GSK added Ojjaara to its portfolio through the acquisition of Sierra in 2022. Credit: Magda Wygralak via Shutterstock. Health ...

DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...

Third quarter results highlight strong operational performance across key value drivers: YUPELRI® (revefenacin) net sales of $62.2 million, recognized by Viatris ...

Saudi Arabia Pharmaceutical Drugs Market is estimated to be valued at US$ 12.60 billion in 2024 and is expected to exhibit a CAGR of 7.6% by 2031 BURLINGAME, CA, UNITED STATES, November 12, 2024 ...

The KSE-100 index of Pakistan Stock Exchange (PSX) lost on Tuesday more than 400 points, weighed down by institutional profit ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...

Concluded targeted enrollment of Phase 3 INDIGO trial evaluating obexelimab for the treatment of Immunoglobulin G4-Related ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

Andrew Witty became CEO of UnitedHealth Group in 2021, but this isn’t his first medical executive gig—he also served as CEO ...

A new generic version of varenicline – originally sold in the UK as Champix by Pfizer – has now been approved for use by the ...